KEY DETAILS
The Los Angeles Times reports that Apothecary Pharma voluntarily recalled 22 vials of tirzepatide injections last month due to a lack of assurance of sterility, and that the recall classification was updated this month to Class II.
Fool.com reports that Novo Nordisk announced a post hoc analysis of a Phase 3 trial showing CagriSema produced almost 25% mean weight loss among 2,309 women, compared with 3% for placebo.
Finance.Yahoo.com reports that Novo's CagriSema achieved 25% weight reduction at 68 weeks in adult women compared with 3% for placebo.
Gdnonline.com reports that Eli Lilly and Mubadala Bio announced a collaboration to advance localised packaging and logistics of Lilly's GLP-1 medicines in Abu Dhabi.
Econotimes.com reports that the Eli Lilly and Mubadala Bio collaboration, announced Oct. 20, will use a 125,000-square-meter site in KEZAD for packaging and warehousing.
The Los Angeles Times reports that Apothecary Pharma, a compounding pharmacy, voluntarily recalled 22 vials of tirzepatide injections last month, and that the recall classification was updated this month to Class II. There is also news from the weight loss pipeline. Fool.com reports that Novo Nordisk announced a post hoc analysis of a Phase 3 trial showing CagriSema produced almost 25% mean weight loss in women, compared with 3% for placebo.
The Los Angeles Times reports that Apothecary Pharma, a compounding pharmacy, voluntarily recalled 22 vials of tirzepatide injections last month due to a lack of assurance of sterility, according to the official announcement. The newspaper reports that the recall classification was updated this month to Class II, meaning exposure to the product may cause temporary or medically reversible adverse health consequences. The Los Angeles Times also quotes an FDA December letter saying that after inspections in September 2024 and visits in January and May 2025, investigators noted serious deficiencies in practices for producing drug products intended to be sterile. The excerpt does not say which company the letter was sent to. The outlet further reports that U.S. inspectors found egregious conditions at two Chinese factories making key components for compounded GLP-1 drugs, including black mold and "gross contamination" at one plant.
The next item is a clinical trial result for CagriSema. Fool.com reports that at The Menopause Society's annual meeting on Tuesday, Novo Nordisk announced a post hoc analysis of a Phase 3 trial showing CagriSema produced an overall mean weight loss of almost 25% among all 2,309 women in the study, compared with 3% for placebo. The outlet notes the figures are based on an ideal where all patients regularly use the drug as directed. Fool.com also reports that in Novo Nordisk's head-to-head Redefine 4 trial against Zepbound's molecule tirzepatide, tirzepatide showed similar or slightly higher efficacy, reaching nearly 26% at the maximum dose. The site adds that weekly U.S. prescriptions for Zepbound overtook those for Wegovy at the start of 2025, with Eli Lilly's drug continuing to hold a commanding lead.
A second outlet reported the same data from a market angle. Finance.Yahoo.com reports that Novo's CagriSema achieved a 25% weight reduction at 68 weeks in adult women, compared with just 3% for placebo, with consistent results across menopausal stages. The outlet reports that analysts expect the drug to generate $11.84 billion in obesity sales by 2028, according to a consensus estimate compiled by FactSet. Finance.Yahoo.com also reports that a European Medicines Agency panel backed Eli Lilly's oral GLP-1 pill, Foundayo (orforglipron), for both obesity and type 2 diabetes in October 2026.
The news also includes a collaboration in Abu Dhabi. Gdnonline.com reports that Eli Lilly and Mubadala Bio have announced a strategic collaboration to advance localised packaging and logistics of Lilly's GLP-1 medicines in Abu Dhabi. The outlet notes that the Emirates Drug Establishment approved Foundayo (orforglipron) for chronic weight management on April 3, 2026, making the UAE the second country in the world to register the medicine. It also reports that in Abu Dhabi, the treatment was introduced for eligible patients under the Personalized Weight Management Program, launched by the Department of Health and the Abu Dhabi Public Health Centre in June 2025.
Another outlet added detail on where that work will happen. Econotimes.com reports that the collaboration, announced Oct. 20, calls for activities to be introduced in phases, subject to technical, quality and regulatory requirements. The outlet reports that the work will use a 125,000-square-meter site in KEZAD that comprises packaging and warehousing facilities.
If you want the full details, the Los Angeles Times has the recall report, and Fool.com and Finance.Yahoo.com both carry the CagriSema data. Gdnonline.com and Econotimes.com have more on the Eli Lilly and Mubadala Bio collaboration in Abu Dhabi.
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.